Dextran Sulfate Treatment Efficiency via Biomarker Group Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological diseases such as Alzheimer's, Parkinson's, and traumatic brain injury lack effective methods to evaluate treatment efficiency and address the complex mechanisms of neuronal damage and cell death, including glutamate excitotoxicity and mitochondrial dysfunction.
Innovation Solution
The method involves determining the efficiency of dextran sulfate treatment by measuring specific biomarkers in patient samples before and after administration, using a group of biomarkers to assess changes in platelet factor 4, tumor necrosis factor superfamily members, brain-derived neurotrophic factor, and other molecules to evaluate treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextran sulfate treatment is administered to patients with neurological diseases, then treatment efficiency can be evaluated through biomarker measurement, but the complexity of evaluating multiple biomarkers increases
Solution Approach 1:
The evaluation system is segmented into multiple biomarker groups (groups 1-6), each targeting specific molecular pathways. This segmentation allows systematic evaluation of different treatment mechanisms separately, making the complex multi-biomarker assessment more manageable and interpretable while maintaining comprehensive treatment monitoring.
Solution Approach 2:
The biomarker panel serves multiple functions simultaneously: it evaluates treatment efficiency, monitors disease progression, and identifies treatment response patterns. This multi-functionality reduces the need for separate evaluation systems and streamlines the overall assessment process despite the complexity of measuring multiple markers.
2Measurement precision
If multiple biomarkers from different groups are measured to comprehensively evaluate treatment efficiency, then evaluation accuracy improves, but measurement time and resource consumption increase
Solution Approach 1:
The biomarkers are pre-categorized into six groups based on their functional relationships and treatment relevance. This preliminary organization allows clinicians to select and measure only the relevant biomarkers for each treatment scenario, reducing measurement time while maintaining comprehensive evaluation accuracy through structured approach.
Solution Approach 2:
The system allows selective measurement of biomarker groups based on specific treatment needs and patient conditions. Clinicians can measure all six groups for comprehensive evaluation or select partial groups when certain biomarkers are sufficient for the clinical question, optimizing the balance between measurement precision and time consumption.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The efficiency of dextran sulfate treatment is determined based on differences between the amount of biomarkers determined in a second biological sample taken from the patient following dextran sulfate administration and in a first biological sample taken from the patient prior to dextran sulfate administration.The biomarkers are selected from 6 groups consisting of PFA4and VAV3 (group 1); TNFSF15, IL-17B, TSLP and CRH(group 2); FGF1 and KITLG (group 3);BDNF, NOG and HBEGF (group 4);AFP,ATP2A3, SLC29A1,SLC40A1 and TTR(group 5);and SLC1A4, SLC7A11, SLC16A7, LDLR and ATP8A1(group 6).